IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2004;45:2625-2639.)
© 2004 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.03-0566
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hare, W. A.
Right arrow Articles by Wheeler, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hare, W. A.
Right arrow Articles by Wheeler, L.

Efficacy and Safety of Memantine Treatment for Reduction of Changes Associated with Experimental Glaucoma in Monkey, I: Functional Measures

William A. Hare, Elizabeth WoldeMussie, Ronald K. Lai, Hau Ton, Guadalupe Ruiz, Teresa Chun, and Larry Wheeler

From the Department of Biological Sciences, Allergan Inc., Irvine, California.

PURPOSE. To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates.

METHODS. Argon laser treatment of the anterior chamber angle was used to induce chronic ocular hypertension (COHT) in the right eye of 18 macaque monkeys. Nine animals were orally dosed daily with 4 mg/kg memantine while the other nine animals received an oral dose of vehicle only. Using both conventional and multifocal methods, recordings of the electroretinogram (ERG) were made at approximately 3, 5, and 16 months after elevation of the intraocular pressure (IOP). Recordings of the visually-evoked cortical potential (VECP) were also made at the 16-month time point.

RESULTS. Chronic ocular hypertension was associated with a reduction in the amplitude of components of the multifocal ERG response and visually-evoked cortical potential. Memantine-treated animals suffered less amplitude reduction for these measures than did vehicle-treated animals, though this treatment effect on the ERG measures was observed only at the early time points (3 and 5 months post IOP elevation). Memantine treatment was not associated with an effect on either the kinetics or amplitude of ERG or VECP response measures obtained from the normotensive eyes.

CONCLUSIONS. Systemic treatment with memantine, a compound which does not lower intraocular pressure, was both safe and effective for reduction of functional loss associated with experimental glaucoma.




This article has been cited by other articles:


Home page
 IOVSHome page
W. Fan, X. Li, and N. G. F. Cooper
CaMKII{alpha}B Mediates a Survival Response in Retinal Ganglion Cells Subjected to a Glutamate Stimulus
Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3854 - 3863.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
R. S. Harwerth, A. S. Vilupuru, N. V. Rangaswamy, and E. L. Smith III
The Relationship between Nerve Fiber Layer and Perimetry Measurements
Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 763 - 773.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Z. He, B. V. Bui, and A. J. Vingrys
The Rate of Functional Recovery from Acute IOP Elevation
Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 4872 - 4880.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
L. Guo, T. E. Salt, A. Maass, V. Luong, S. E. Moss, F. W. Fitzke, and M. F. Cordeiro
Assessment of Neuroprotective Effects of Glutamate Modulation on Glaucoma-Related Retinal Ganglion Cell Apoptosis In Vivo
Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 626 - 633.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
Y. H. Yucel, N. Gupta, Q. Zhang, A. P. Mizisin, M. W. Kalichman, and R. N. Weinreb
Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma.
Arch Ophthalmol, February 1, 2006; 124(2): 217 - 225.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
W. A. Hare, E. WoldeMussie, R. N. Weinreb, H. Ton, G. Ruiz, M. Wijono, B. Feldmann, L. Zangwill, and L. Wheeler
Efficacy and Safety of Memantine Treatment for Reduction of Changes Associated with Experimental Glaucoma in Monkey, II: Structural Measures
Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2640 - 2651.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Association for Research in Vision and Ophthalmology